GlaxoSmithKline (GSK) is moving ahead with a global restructuring program that is on track to deliver a target of £2.2 billion
($3.6 billion) of annual savings by 2012. These savings have been extracted from GSK's developed-country sales and marketing
structure, support functions, R&D, and manufacturing infrastructure. Along with these changes are increased investment in
emerging markets, according to the company's 2010 annual filing.
In emerging markets, in June 2011, GSK agreed to acquire Shenzhen Neptunus Interlong Bio-Technique's stake in the companies'
previously formed joint venture, Shenzhen GSK–Neptunus Biologicals, for $39 million. The joint venture develops and manufactures
seasonal and pandemic influenza vaccines in China, Hong Kong, and Macau. In December 2010, GSK agreed to acquire the Chinese
pharmaceutical company, Nanjing MeiRui Pharma, including a manufacturing facility in Nanjing City, Jiangsu Province, China.
In Russia, GSK formed an alliance with JSC Binnopharm for the local secondary manufacture of several GSK vaccines. Under
this alliance, which was announced in November 2010, GSK will supply bulk vaccine and provide technology and expertise to
enable Binnopharm to undertake the secondary manufacture, including filling and packaging of GSK vaccines. Binnopharm will
be responsible for gaining approval of their facilities to allow supply of GSK cervical cancer, rotavirus, and pneumococcal
vaccines under Binnopharm's trademark for the Russian public market.
In biologics, in September 2010, GSK and the Swiss custom manufacturing organization Lonza formed an agreement under which
Lonza will supply manufacturing capacity for five GSK early-stage monoclonal antibodies. Lonza will initially manufacture
clinical-trial batches of five compounds currently in Phase I and II development and provide flexible capacity for late-stage
development and commercial launch. As part of the agreement, GSK will work with Lonza to assess options for the design, specification,
location, and construction of a biopharmaceutical manufacturing facility within the United Kingdom.
Also, in 2010, GSK sold its Cidra, Puerto Rico, facility after the plant's closure in 2009, which followed manufacturing problems
and a subsequent FDA consent decree for the facility in the early 2000s.